| Overview |
| bs-4272R |
| CHFR Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CHFR |
| 41-140/664 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 55743 |
| Nucleus |
| Checkpoint with forkhead and ring finger domains; Checkpoint with forkhead and RING finger domains protein; E3 ubiquitin protein ligase CHFR; EC 6.3.2.; RING finger protein 196; RNF 116; RNF 196; RNF116; RNF196; Ubiquitin ligase protein; CHFR_HUMAN. |
| A number of human cancers are sensitive to mitotic stress, implying checkpoint defects. Many proteins that contain forkhead-associated (FHA) domains are cell cycle checkpoints and CHFR is one such protein. It has a FHA and ring finger domain within its N terminus. Within its C terminus, CHFR contains a cysteine-rich region that did not display significant similarity to any protein in the GenBank database, but is highly conserved between humans and mice. It has been concluded that CHFR defines a checkpoint that delays entry into metaphase in response to mitotic stress. It has been found CpG methylation-dependent silencing of CHFR expression occurs in 45% of cancer cell lines, 40% of primary colorectal cancers, 53% of colorectal adenomas, and 30% of primary head and neck cancers. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz